News & Trends - Biotechnology

Revolutionary radiation drugs to brings hope for cancer patients

Health Industry Hub | March 24, 2020 |
[Total: 1    Average: 4/5]

Biotech News: People with hard-to-reach cancers in the kidney, gut and prostate will have improved hope for early diagnosis and treatment with new research aimed at increasing the shelf life of revolutionary radiation drugs.

Funding of $AU 2.5 million will kickstart a two-year manufacturing research project that will harness the combined expertise of the University of Melbourne and the Peter MacCallum Cancer Centre to increase the shelf-life of radiation drugs, so they can be shipped to patients globally.

Telix Pharmaceuticals and Cyclotek, with co-funding from of the Innovative Manufacturing Cooperative Research Centre (IMCRC), will contribute AU$1 million to the project and will lead the research to create a manufacturing production process. They will also work with external partners, iphase Technologies and GenesisCare, to develop and streamline the manufacturing process.

Customer engagement during COVID-19. Health Industry Hub combines expertise in delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry.

Radiation drugs, known as ‘radiopharmaceuticals’, can be used to locate and see cancer cells in the body, including hard-to- reach places using the imaging technology, Positron Emission Tomography (PET).

By capturing the radio isotope in a selective ‘cage like’ molecule and fusing it to a targeting molecule, the radiation can be directly transported to the cancerous cells for detection of tumours.

In the case of kidney, neuroendocrine and prostate cancers, there are specific ‘homing’ molecules that can transport the radioactive cargo to the cancer cells, including those that are hidden in the hard-to-reach nooks and crannies of the body like the gut, kidney and prostate.

Again, the process makes it possible to diagnose cancer cells that would otherwise go undetected. Once diagnosed, a higher energy radioisotope can then be used to destroy the cancer cells.

Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

The ability of the drugs to target cancer cells also reduces the number of healthy cells that are damaged by more traditional ways of administering radiation therapy.

“It has taken years of basic research at the School of Chemistry and Bio21 Institute to develop the carrier compounds that are the principle behind this technology,” said University of Melbourne Professor Paul Donnelly from the School of Chemistry and Bio21 Institute.

“It’s exciting to see these compounds being developed for clinical use and manufacture.”

Currently, isotopes are being produced locally within the Peter MacCallum Cancer Centre for cancer patients by the company, Cyclotek.

“The challenge is to create radio-labelled diagnostic and therapeutic agents with a longer half-life, that lend themselves to manufacture and distribution beyond the hospital walls,” said Michael Wheatcroft of Telix Pharmaceuticals.

Mr David Chuter, the CEO and Managing Director of the Innovative Manufacturing CRC, said the  manufacturing research project will open up a world of potential to treat cancer more effectively.

“The project will build the foundation to safely and cost-effectively manufacture life changing targeted cancer radiation drugs in Australia, and export them to the world.”


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Medical

Medical News - Paramedics Association concerned over uni students being thrown in to COVID-19 frontline

Paramedics Association concerned over uni students being thrown in to COVID-19 frontline

Health Industry Hub | April 1, 2020 |

The Australian Paramedics Association NSW (APA(NSW)) has significant concerns for the safety of patients, Paramedics and university students after NSW […]

More


News & Trends - Medical Technology

MedTech News - Australia's private hospitals join the COVID-19 fight in new partnership

Australia’s private hospitals join the COVID-19 fight in new partnership

Health Industry Hub | April 1, 2020 |

A new partnership with the Commonwealth Government will guarantee the viability of Australia’s private hospital sector, ensuring its full capacity […]

More


News & Trends - Pharmaceuticals

Pharma News - Roche's adjuvant treatment PBS listed in early breast cancer

Roche’s adjuvant treatment PBS listed in early breast cancer

Health Industry Hub | April 1, 2020 |

Effective 1st April 2020, Roche’s Kadcyla is listed on the Pharmaceutical Benefits Scheme (PBS), for the adjuvant treatment of patients […]

More


Leadership & Management

Leadership & Management - Bill Gates's insights on COVID-19 global pandemic

Bill Gates’s insights on COVID-19 global pandemic

Health Industry Hub | April 1, 2020 |

In a recent TED Talk, philanthropist and Microsoft co-founder Bill Gates offers insights into the COVID-19 pandemic, discussing why testing […]

More